Brivanib in combination with Notch3 silencing shows potent activity in tumour models

BACKGROUND: Sorafenib is the first targeted agent proven to improve survival of patients with advanced hepatocellular carcinoma (HCC) and it has been used in first line treatments with heterogeneous response across patients. Most of the promising agents evaluated in first-line or second-line phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannini, Catia, Salzano, Anna Maria, Baglioni, Michele, Vitale, Monica, Scaloni, Andrea, Zambrano, Nicola, Giannone, Ferdinando Antonio, Vasuri, Francesco, D’Errico, Antonia, Svegliati Baroni, Gianluca, Bolondi, Luigi, Gramantieri, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461893/
https://www.ncbi.nlm.nih.gov/pubmed/30765875
http://dx.doi.org/10.1038/s41416-018-0375-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461893/
https://www.ncbi.nlm.nih.gov/pubmed/30765875
http://dx.doi.org/10.1038/s41416-018-0375-4

Ejemplares similares